AGTC is focused on the research and development of novel therapeutics for patients with unmet medical needs utilizing AGTC's proprietary, non-pathogenic adeno-associated virus (AAV) delivery system. AGTC has demonstrated that this system can be used to deliver a normal form of a gene in both animals and humans thus allowing their own body to produce sustained therapeutic levels of important biologics.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/19/12 | $37,500,000 | Series B |
Alta Partners InterWest Partners Osage University Partners S.R. One | undisclosed |
